You are here

  • Home
  • Archive
  • Volume 8, Issue 1
  • Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial

Article metrics

Article menu

This article has a correction. Please see:

Download PDFPDF

XML
Clinical/translational cancer immunotherapy
Original research
Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial

 

Online download statistics by month:

Online download statistics by month: May 2020 to July 2025

AbstractFullPdf
May 2020313313140
Jun 202015315354
Jul 2020696937
Aug 2020615919
Sep 2020535324
Oct 2020414135
Nov 2020444556
Dec 202026269
Jan 2021444330
Feb 2021575744
Mar 2021606023
Apr 2021363527
May 2021373722
Jun 2021434321
Jul 2021666637
Aug 2021575745
Sep 2021595944
Oct 2021828258
Nov 2021616155
Dec 2021505043
Jan 2022656933
Feb 2022464743
Mar 2022627242
Apr 2022646833
May 2022616636
Jun 2022575824
Jul 2022454733
Aug 2022565637
Sep 2022464632
Oct 2022525629
Nov 2022323422
Dec 2022474829
Jan 2023404027
Feb 2023888833
Mar 2023616228
Apr 2023464622
May 2023364028
Jun 2023404023
Jul 2023414126
Aug 2023424323
Sep 2023373713
Oct 2023424217
Nov 2023494924
Dec 2023444423
Jan 2024293020
Feb 2024525223
Mar 2024666656
Apr 2024383827
May 2024383822
Jun 2024414029
Jul 2024474916
Aug 2024232413
Sep 2024333328
Oct 2024515129
Nov 2024515230
Dec 2024454629
Jan 2025484824
Feb 202510510539
Mar 2025525230
Apr 2025696932
May 2025414325
Jun 2025171712
Jul 2025110
Total345835021987